In a recent study posted to Research Square* and under consideration at the Journal of Nanobiotechnology, researchers developed a hybrid assay incorporating immunological antibody-based viral spike (S) protein capture with molecular nucleic acid amplification by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). This assay could be used for the rapid and precise detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virions.
Study: Immunomolecular Assay Based on Selective Virion Capture by Spike Antibody and Viral Nucleic Acid Amplification for Detecting Intact SARS-CoV-2 Particles. Image Credit: NicoElNino/Shutterstock
This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources
Background
Mutations in the SARS-CoV-2 S protein enhance viral binding with host angiotensin-converting enzyme 2 (hACE2) receptors. This facilitates viral evasion of host immune responses and enhances viral entry into host cells. Once SARS-CoV-2 enters the nucleus, virions comprising single-stranded ribonucleic acid (RNA), polymerases, and proteins are synthesized. Since studies show that novel SARS-CoV-2 variants with S protein mutations are responsible for increased virulence, therapeutic strategies that target the S protein-associated-virion synthesis could decrease viral infectivity.
Methods such as chest computed tomography (CT), Raman spectroscopy, median tissue culture infective dose determination, viral antigen assays, antibody detection, and nucleic acid amplification are independently ineffective in viral diagnosis with high false-positive results due to the presence of capsid or genome-deficient subviral particles in the serum. Factors such as long testing duration, low specificity, high viral loads, complicated viral isolation procedures, and specific environmental needs for virion detection necessitate the formulation of improved diagnostic methods.
To this end, the authors of this study devised a hybrid technique involving the use of serological antibodies and molecular amplification of nucleic acids for precise detection and quantification of complete virions.
About the study
The researchers designed a pseudovirus that simulated SARS-CoV-2 function in the present study. Eleven SARS-CoV-2 strains were screened for S protein-targeted antibodies. These specific monoclonal antibodies were used to capture the S protein that underwent qRT-PCR for viral nucleic acid amplification.
The pseudovirus contained two types of plasmids: an envelope plasmid, pCMV3-2019-nCoV-Spike (S1+S2), and a lentivirus-transfected plasmid, pLV-SARS-CoV-2-F1abFabNE-GFP, that encoded for a green fluorescence protein (GFP). These plasmids were transfected for the expression of four incomplete genes: ORFab, ORF1ab, M, and N genes in the pseudovirus.
The plasmids were co-transfected to enhance the function of the S protein. Pseudovirus infectivity was assessed by observing the green fluorescence emitted by the GFPs in transduced HEK-293FT-hACE2 cell lines.
To evaluate the effectiveness of incorporating the S glycoprotein and the genetic sequences in the pseudovirus, mouse anti-S was subjected to western blot and molecular qRT-PCR, respectively. The sensitivity of the hybrid assay was evaluated by testing the pseudovirus against S protein-affinity antibodies and carboxyl magnetic beads. The pseudovirus was tested against varying titers of hepatitis B virus (HBV) to detect its stability against other viruses in human serum. The pseudovirus was subjected to different samples such as plastic, paper, copper, and aluminum to determine the most appropriate environmental conditions.
Results
Abundant GFP fluorescence and positive signals in PCR for the F1ab gene indicated successful generation of the functionally simulated SARS-CoV-2 pseudovirus. In the western blot, specific bands at 80 and 190 kDa representative of S2 and (S1 +S2) domains of the S protein, respectively, were obtained, indicating successful S protein incorporation in the pseudovirus structure.
Active viral S glycoproteins were detected only with three out of the 11 identified monoclonal antibodies: M1E1, CQ25, and CQ2, among which the CQ25 or anti-S antibody showed the highest specificity. A viral titer of 9×102 transduction units/mL exclusive of incomplete virions and subviral particles could be effectively detected and quantified using molecular qRT-PCR amplification.
The variation coefficients were 2% and 1.5% for inter-assay and intra-assay of viral stability against HBV, indicating stable and specific qualitative and quantitative detection of SARS-CoV-2 virions by the hybrid assay.
The pseudovirus demonstrated the highest stability on plastic, and least stability on copper with viable titers of complete virions detected up to four days on plastic, paper, and aluminum, although the efficacy decreased with time.
Conclusion
The authors concluded that the novel hybrid immune-molecular assay was a cost-effective and convenient method for precisely detecting and quantifying SARS-CoV-2 virions.
This assay could be used to monitor infectivity of post-discharge and convalescent patients; evaluate high-risk zones such as operation theatres, airtight cabins, cold-chain logistics, and isolation rooms; and detect complete virions of causative viruses of several infections such as Hepatitis C and B, influenza, and acquired immunodeficiency syndrome (AIDS). This immune-molecular detection could enhance diagnostic accuracy and facilitate the development of S-protein targeted therapeutic strategies.
This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources
Article Revisions
- Mar 15 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Study finds nirmatrelvir-ritonavir reduces severe COVID-19 and long COVID risks in high-risk patients